Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review
Open accessThe DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Current pharmacotherapies for major depressive disorder (MDD) and bipolar depression (BDep) have a distinct lag of onset that can generate great distress and impairment in patients. Furthermore, as demonstrated by several real-world effectiveness trials, their efficacy is limited. All approved antidepressant medications for MDD primarily act through monoaminergic mechanisms, agonists or antagonists with varying affinities for serotonin, norepinephrine and dopamine. The glutamate system has received much attention in recent years as an avenue for developing novel therapeutics. A single subanesthetic dose infusion of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has been shown to have rapid and potent antidepressant effects in treatment-resistant MDD and BDep. In a reverse translational framework, ketamine’s clinical efficacy has inspired many preclinical studies to explore glutamatergic mechanisms of antidepressant action. These studies have revealed enhanced synaptic plasticity/synaptogenesis via numerous molecular and cellular mechanisms: release of local translational inhibition of brain-derived neurotrophic factor and secretion from dendritic spines, mammalian target of rapamycin activation and glycogen synthase kinase-3 inhibition. Current efforts are focused on extending ketamine’s antidepressant efficacy, uncovering the neurobiological mechanisms responsible for ketamine’s antidepressant activity in biologically enriched subgroups, and identifying treatment response biomarkers to personalize antidepressant selection. Other NMDA receptor antagonists have been studied both preclinically and clinically, which have revealed relatively modest antidepressant effects compared with ketamine but potentially other favorable characteristics, for example, decreased dissociative or psychotomimetic effects; therefore, there is great interest in developing novel glutamatergic antidepressants with greater target specificity and/or decreased adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated postsynaptic activity triggers BDNF release and TrkB receptor activation, which in turn engages mechanistic target of rapamycin complex 1 (mTORC1) dependent translational programs supporting dendritic spine growth and synaptic strengthening [20,42,48,49,50].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The result is a brief but robust glutamate surge that drives enhanced α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) throughput and calcium influx, including through calcium permeable AMPA channels [20,42,47].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At subanesthetic doses, ketamine preferentially antagonizes N-methyl-D-aspartate receptors (NMDARs) on fast spiking GABAergic interneurons, releasing pyramidal neurons from inhibitory control [42,43,44,45,46].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [42]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 258 · cited 2×
“In the only published study of patients who were acutely suicidal and encountered in an emergency setting, open-label intravenous ketamine (0.2 mg/kg intravenous push over 1–2 min) had both acute antidepressant and antisuicidal effects in 14 patients with depression [Larkin and Beautrais, 2011].”
BackgroundInfluentialRetractedMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · cited 1×
“In preclinical models of despair, ketamine activates mammalian target of rapamycin (mTOR), which is a critical hub of cellular growth and proliferation [Hay and Sonenberg, 2004].”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“HDRS scores significantly decreased with ketamine compared with placebo within 240 min and were maintained for at least 3 days [Berman et al. 2000].”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“Ketamine increased mTOR phosphorylation and other downstream molecular targets critical for transcriptional activation within 1 hour of administration [Li et al. 2010].”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“However, because ketamine inhibits eEF-2K functioning, eEF-2 activity predominates, which results in greater local BDNF translation in dendritic spines [Autry et al. 2011].”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Preclinical studies The prevailing cellular and molecular hypotheses for ketamine’s mechanism of action is that NMDA receptor blockade on cortical γ-aminobutyric acid(GABA)ergic interneurons releases the tonic inhibition on major output neurons, for example, cortical pyramidal cells [Moghaddam et al. 1997].”
BackgroundSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 1×
“Over the course of the last 15 years, ketamine’s rapid and robust antidepressant properties in MDD and BDep have been labeled by some leaders in the field as ‘arguably the most important discovery (in depression research) in half a century’ [Duman and Aghajanian, 2012].”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Research works printed but not linked: 3
- Sanacora G., 2014, Poster presented on 18 June at the 2014 American Society of Clinical Psychopharmacology Annual Meeting
- Sos P., 2013, Neuro Endocrinol Lett, 34, 287
- Wan L., 2014, J Clin Psychiatry
Cited by
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
The neurobiology of depression: An integrated view
Dean, J., & Keshavan, M. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.025 · Cited by 765
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Self-citationThe orbitofrontal cortex and emotion in health and disease, including depression
Rolls, E. T. (2019) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2017.09.021 · Cited by 329
“Treatments that can reduce depression such as a single dose of ketamine (Iadarola et al., 2015) may act in part by quashing the attractor state in the lateral orbitofrontal cortex/ventrolateral prefrontal cortex at least temporarily (though there is also evidence that ketamine’s effect on depression may be related to…”
Nutrition and behavioral health disorders: depression and anxiety
Kris-Etherton, P. M., Petersen, K. S., Hibbeln, J. R., Hurley, D., Kolick, V., Peoples, S., Rodriguez, N., & Woodward-Lopez, G. (2021) · Nutrition Reviews · doi:10.1093/nutrit/nuaa025 · Cited by 318
“overactivates the glutamatergic receptor (N-methyl-Daspartate), and is implicated in depression.(75) Higher intake of vitamin B12 and folate is associated with lower risk of depression in epidemiological studies,(76,77) although it is unclear whether vitamin B12 and folate adequacy prevents the onset of depression.”
Background
Metadata
- Authors
- Iadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- National Institutes of Health/National Institute of Mental Health, Experimental Therapeutics and Pathophysiology Branch, Bethesda, MD, USA
- Venue
- Therapeutic Advances in Chronic Disease
- Publisher
- SAGE Publications
- Published
- 2015-04-13
- Volume
- 6
- Issue
- 3
- Pages
- 97-114
- ISSN
- 2040-6223 (ISSN-L)
- 2040-6231
- PMC
- PMC4416968
- OpenAlex
- W2055661286
- Cited by
- 201
- References
- 104
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 11 · 2023: 10 · 2022: 16 · 2021: 20 · 2020: 16 · 2019: 24 · 2018: 20 · 2017: 16 · 2016: 35 · 2015: 16
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Update notices
- correction (2016-05-17)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Chronic Disease (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- ketamine, NMDA receptor antagonists, major depressive disorder, bipolar depression, treatment-resistant depression, rapid antidepressant effects, synaptic plasticity, brain-derived neurotrophic factor, mTOR, glycogen synthase kinase-3, treatment response biomarkers, antidepressant treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. https://app.cochat.ai/papers/10.1177/2040622315579059
- The paper
- Iadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015). Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Therapeutic Advances in Chronic Disease. https://doi.org/10.1177/2040622315579059
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.